Evidence map›Paper›PMID 37609205›Full record

ArticleResearch square2023

Novel data-driven subtypes and stages of brain atrophy in the ALS-FTD spectrum.

Ting Shen, Jacob W Vogel, Jeffrey Duda, Jeffrey S Phillips, Philip A Cook, James Gee, Lauren Elman, Colin Quinn, Defne A Amado, Michael Baer and 4 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Ting ShenUniversity of Pennsylvania Perelman School of Medicine.ORCID 0000-0002-3937-4427
Jacob W VogelLund University.
Jeffrey DudaUniversity of Pennsylvania Perelman School of Medicine.
Jeffrey S PhillipsUniversity of Pennsylvania Perelman School of Medicine.
Philip A CookUniversity of Pennsylvania Perelman School of Medicine.
James GeeUniversity of Pennsylvania Perelman School of Medicine.
Lauren ElmanUniversity of Pennsylvania Perelman School of Medicine.
Colin QuinnUniversity of Pennsylvania Perelman School of Medicine.
Defne A AmadoUniversity of Pennsylvania Perelman School of Medicine.
Michael BaerUniversity of Pennsylvania Perelman School of Medicine.
Lauren MassimoUniversity of Pennsylvania Perelman School of Medicine.
Murray GrossmanUniversity of Pennsylvania Perelman School of Medicine.
David J IrwinUniversity of Pennsylvania Perelman School of Medicine.
Corey T McMillanUniversity of Pennsylvania Perelman School of Medicine.
University of Pennsylvania · USLund University · SE

Funding

Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Lauren M Massimo · 2020 to 2026
$18.8M
Spreading Tau Pathology in Non-Amnestic Alzheimer's DiseaseR01AG054519 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jeffrey S Phillips · 2018 to 2026
$7.4M
SCHIZOPHRENIA: A NEUROPSYCHIATRIC PERSPECTIVET32MH019112 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E · 1990 to 2024
$6.2M
Microscopic and Large-Scale Networks of Molecular Pathology in Frontotemporal Lobar DegenerationR01NS109260 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI IRWIN, DAVID JOHN · 2019 to 2023
$3.8M
A Network Neuroscience Investigation of Disease Spread in Non-Amnestic Mild Cognitive ImpairmentK01AG061277 · NIA · UNIVERSITY OF PENNSYLVANIA · PI PHILLIPS, JEFFREY S · 2019 to 2023
$583k
NIA NIH HHS K01 AG061277NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG072979NIA NIH HHS R01 AG054519NIMH NIH HHS T32 MH019112NINDS NIH HHS R01 NS109260
6 · The paper itself

Abstract

Background: TDP-43 proteinopathies represents a spectrum of neurological disorders, anchored clinically on either end by amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD). The ALS-FTD spectrum exhibits a diverse range of clinical presentations with overlapping phenotypes, highlighting its heterogeneity. This study aimed to use disease progression modeling to identify novel data-driven spatial and temporal subtypes of brain atrophy and its progression in the ALS-FTD spectrum. Methods: We used a data-driven procedure to identify 13 anatomic clusters of brain volumes for 57 behavioral variant FTD (bvFTD; with either autopsy-confirmed TDP-43 or TDP-43 proteinopathy-associated genetic variants), 103 ALS, and 47 ALS-FTD patients with likely TDP-43. A Subtype and Stage Inference (SuStaIn) model was trained to identify subtypes of individuals along the ALS-FTD spectrum with distinct brain atrophy patterns, and we related subtypes and stages to clinical, genetic, and neuropathological features of disease. Results: SuStaIn identified three novel subtypes: two disease subtypes with predominant brain atrophy either in prefrontal/somatomotor regions or limbic-related regions, and a normal-appearing group without obvious brain atrophy. The Limbic-predominant subtype tended to present with more impaired cognition, higher frequencies of pathogenic variants in Conclusions: Our findings suggest distinct neurodegenerative subtypes of disease along the ALS-FTD spectrum that can be identified

Indexed as

amyotrophic lateral sclerosisdisease heterogeneityfrontotemporal degenerationSuStaIn model

Identifiers

PMID37609205
PMCPMC10441467
OpenAlexW4385740701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.